Home / Innere Medizin / Onkologie / ESMO 2018: „Exzellente Ergebnisse mit Immuntherapie beim Kolorektalkarzinom“
Assoz.-Prof. Dr. Renate Schaberl-Moser

ESMO 2018: „Exzellente Ergebnisse mit Immuntherapie beim Kolorektalkarzinom“

Assoz.-Prof. Dr. Renate Schaberl-Moser, Universitätsklinik für Innere Medizin, Graz, kommentiert die neuen Kolorektalkarzinom-Studien, darunter beeindruckende Immuntherapie-Ergebnisse und Updates, die den Standard bestätigen. Praxisverändernde Daten gab es beim Analkarzinom.

1=Korrektur zum Video: 445 Patienten mit metastasiertem Kolorektalkarzinom und BRAF-Wildtyp wurden innerhalb der MODUL-Studie zu einer Erhaltungstherapie randomisiert, davon erhielten 297 Patienten Fluorpyrimidin/Bevacizumab/Atezolizumab und 148 Patienten erhielten Fluorpyrimidin/Bevacizumab (Grothey A et al., LBA19)

 

Abstracts

456PD - Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer
T. Reinert

LBA22 - Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus Pan or singleagent Pan: translational analyses of the VALENTINO study
F. Morano

LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite InstabilityHigh/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC)
H.-J. Lenz

LBA37_PR - Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer; ESMO 2018;
M. Chalabi

LBA19 - Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
A. Grothey

453PD - 1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK0109)
M. Geissler

LBA20 - TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).
C. Cremolini

LBA21 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results
C. Hulme

Quelle: ESMO 2018

LOGIN

Login

Passwort vergessen?